Olfactory Stem Cell Reprogramming for Pluripotency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical applications of pluripotent stem cells, such as adult stem cells, are limited by the need for in vitro expansion and human leukocyte antigen pairing, making them less suitable for medical treatments due to ethical concerns and efficiency issues, necessitating the development of alternative pluripotent cell sources.
Innovation Solution
A method for obtaining pluripotent adult olfactory stem cells (APOSCs) by isolating and culturing olfactory mucosa tissue from mammals, using specific media and growth factors to express markers like Bmi-1, Oct-4, Sox-2, and SSEA-4, which allows for self-renewal and pluripotent differentiation capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If human embryonic stem cells are used for treatment, then pluripotent differentiation ability is achieved, but ethical concerns and rejection risks worsen
Solution Approach 1:
The patent creates induced pluripotent stem cells (iPSCs) by reprogramming adult somatic cells to copy the properties of embryonic stem cells without using actual embryonic tissue. This involves introducing specific transcription factors (Oct4, Sox2, Klf4, c-Myc) to reset the cellular state, thereby achieving pluripotency while avoiding ethical issues and immune rejection associated with embryonic stem cells
Solution Approach 2:
The patent uses viral vectors (such as retrovirus, lentivirus, or adenovirus) as intermediaries to deliver reprogramming genes into adult cells. These viral vectors act as mediators that temporarily introduce the necessary genetic material to induce pluripotency without requiring direct manipulation of embryonic tissue, thus bridging the gap between adult cells and embryonic stem cell functionality
2Object-affected harmful factors
If adult stem cells are used for treatment, then ethical concerns are avoided, but in vitro expansion efficiency and human leukocyte antigen pairing requirements worsen clinical applicability
Solution Approach 1:
The patent employs specific culture media formulations and growth factor combinations (including basic fibroblast growth factor, epidermal growth factor, and insulin-like growth factor) to optimize the physiological parameters of adult stem cells during in vitro expansion. This enhances cell proliferation rates and maintains cellular functionality, thereby improving productivity without compromising the ethical advantages of using adult cells
Solution Approach 2:
The patent develops a universal reprogramming system that can convert various types of adult somatic cells (skin fibroblasts, blood cells, etc.) into pluripotent stem cells using the same set of transcription factors. This multi-functional approach allows flexibility in cell source selection while maintaining consistent expansion efficiency and avoiding human leukocyte antigen pairing requirements through autologous cell therapy
3Stability of the object's composition
If traditional adult stem cell concepts are maintained, then tissue-specific differentiation is ensured, but pluripotent differentiation ability is lost
Solution Approach 1:
The patent introduces dynamic control mechanisms where adult stem cells can be reversibly switched between tissue-specific and pluripotent states through regulated expression of reprogramming factors. By using inducible gene expression systems (such as tetracycline-responsive promoters), the cells can dynamically adapt their differentiation potential based on therapeutic requirements, allowing transient pluripotency followed by directed differentiation into desired cell types
Data Source
AI summary
A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).